ArticleVeterinary sciences2025
Molecular Epidemiology and Genetic Evolution Analysis of Porcine Reproductive and Respiratory Syndrome Virus in Southern Xinjiang, China, from 2023 to 2025.
Article in Veterinary sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Detection, virus isolation, and phylogenetic analysis of PRRSV2 in China from 2022 to 2025.Porcine health management · 2026Article
- Emergence of a Candidate Novel Sub-Genotype 1.1d of Classical Swine Fever Virus in India: Insights from a Comprehensive NS5B Gene Analysis and Multi-Locus Phylogeny.Current microbiology · 2026Article
- Development of a High-Resolution Melting (HRM)-Based Multiplex Real-Time PCR Assay of PEDV, TGEV, PoRV, PDCoV, PRV, and PRRSV.Transboundary and emerging diseases · 2026Article
- Longitudinal Molecular Epidemiology and Genomic Evolution of Porcine Reproductive and Respiratory Syndrome Virus in a Large-Scale Swine Production System in Northern China, 2023-2026.Transboundary and emerging diseases · 2026Article
- Molecular epidemiology and genetic evolution of PRRSV ORF5 in Sichuan, Southwest China.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV), a major pathogen causing substantial economic losses in the global swine industry, was studied in southern Xinjiang to characterize its local epidemic features. Based on 632 clinical samples collected from 13 pig farms between 2023 and 2025, quantitative RT-PCR detection showed an overall positivity rate of 18.35% (116/632), with PRRSV-2 single infection accounting for 97.41% (113/116), PRRSV-1 single infection for 1.72% (2/116), and co-infection for 0.86% (1/116). Among 38 ORF5 sequences obtained from positive samples, Sublineage 1.8 (NADC30-like) was dominant, comprising 97.14% of successfully sequenced strains. Molecular analysis revealed that PRRSV-1 isolates carried six amino acid mutations including A129V (consistent with the Chinese strain CN/FJFQ-1/2023), while PRRSV-2 strains exhibited key variations such as the neutralization escape mutation Q13R, virulence-associated site K151R, and an anomalous vaccine marker A137. Furthermore, a recombinant strain (XJLETUQ2025-7) between NADC30 and VR-2332 was identified with breakpoints in NSP2 and NSP10. Serological surveillance of 2043 vaccinated pigs showed an overall antibody positive rate of 83.0% (1696/2043), with increasing annual rates from 72.3% (2023) and 75.4% (2024) to 91.3% (2025). In conclusion, the PRRSV epidemic in southern Xinjiang is primarily driven by NADC30-like strains of PRRSV-2, with recombination events and GP5 epitope variations posing challenges to disease control. These findings enhance the epidemiological understanding of PRRSV in the region and provide valuable insights for vaccine development and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.